Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials

Pain

Volumn 111, Issue 3, 2004, Pages 286-296

  Edwards, Jayne E ^a   McQuay, Henry J ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti inflammatory; Arthritis; Valdecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VALDECOXIB;

ABDOMINAL PAIN; ARTHRALGIA; BLOOD DISEASE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DYSPEPSIA; GASTRIC OUTLET SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMATEMESIS; HUMAN; KIDNEY DISEASE; MELENA; META ANALYSIS; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; STOMACH EROSION; STOMACH ULCER; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VOMITING;

EID: 4444220488     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2004.07.004     Document Type: Article

References (31)

1. Anon Bextra (Valdecoxib) Tablets, application no. 21-341. Centre for Drug Evaluation and Research, Food and Drug Administration. URL: Http: //Www.Fda.Gov/Cder/Foi/Nda/2001/21-341_Bextra.Htm.
2. W. Bensen, A. Weaver, L. Espinoza, W.W. Zhao, W. Riley, B. Paperiello, and D.P. Recker Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen Rheumatology (Oxford) 41 2002 1008 1016
3. Vigor Study Group, C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkat, M.C. Hochberg, T.K. Kvien, and C. Schnitzer Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
4. R.J. Cook, and D.L. Sackett The number needed to treat: a clinically useful measure of treatment effect Br Med J 310 1995 452 454
5. B. Crichton, and M. Green GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the pain in osteoarthritis Curr Med Res Opinion 18 2002 92 96
6. J.J. Deeks, L.A. Smith, and M.D. Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Br Med J 325 2002 1 8
7. A.M. Elliott, B.H. Smith, K.I. Penny, W.C. Smith, and W.A. Chambers The epidemiology of chronic pain in the community Lancet 354 1999 1248 1252
8. A. Garcia-Rodriguez, and S. Hernandez-Diaz Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure Epidemiology 14 2003 240 246
9. S. Garner, D. Fidan, R. Frankish, M. Judd, T. Towheed, G. Wells, and P. Tugwell Rofecoxib for rheumatoid arthritis (cochrane review) The Cochrane Library, Issue 3 2003 Update Software Oxford
10. D.J. Gavaghan, R.A. Moore, and H.J. McQuay An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data Pain 85 2000 415 424
11. C. Harley, and S. Wagner Persistence with COX-2 inhibitors in managed care: an analysis of claims data Managed Care Interface 16 2003 38 45
12. C. Hawkey, L. Laine, T. Simon, A. Beaulieu, J. Maldonado-Cocco, E. Acevedo, A. Shahana, H. Quan, J. Bolognese, and E. Mortensen Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis Arthritis Rheum 43 2000 370 377
13. Rofecoxib Rheumatoid Arthritis Endoscopy Study Group, C.J. Hawkey, L. Laine, T. Simon, H. Quan, S. Shingo, and J. Evans Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study Gut 52 2003 820 826
14. D. Henry, J. Page, I. Whyte, R. Nanra, and C. Hall Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study Br J Clin Pharmacol 44 1997 85 90
15. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and H.J. McQuay Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
16. A. Kivitz, G. Eisen, W.W. Zhao, T. Bevirt, and D.P. Recker Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis J Fam Pract 51 2002 530 537
17. L. Laine, J. Wogen, and H. Yu Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs Gastroenterology 125 2003 389 395
18. W. Makarowski, W.W. Zhao, T. Bevirt, and D.P. Reckert Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen Osteoarthritis Cartilage 10 2002 290 296
19. M. Mamdani, P.A. Rochon, D.N. Juurlink, A. Kopp, G.M. Anderson, G. Naglie, P.C. Austin, and A. Laupacis Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs Br Med J 325 2002 624 629
20. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled: the QUOROM statement Lancet 354 1999 1896 1900
21. R.A. Moore, and C.J. Phillips Cost of NSAID adverse effects to the UK National Health Service J Med Econ 2 1999 45 55
22. R. Moore, J. Edwards, and H. McQuay Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports BioMed Central Urol 2 2002 6
23. J.A. Morris, and M.J. Gardner Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates M.J. Gardner D.G. Altman Statistics with confidence-confidence intervals and statistical guidelines 1995 British Medical Journal London 50 63
24. J. Page, and D. Henry Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem Arch Intern Med 160 2000 777 784
25. K. Pavelka, D.P. Recker, and K.M. Verburg Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial Rheumatology (Oxford) 42 2003 1 9
26. D.H. Sikes, N.M. Agrawal, W.W. Zhao, J.D. Kent, D.P. Recker, and K.M. Verburg Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis Eur J Gastroenterol Hepatol 14 2002 1101 1111
27. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. Celecoxib long-term arthritis safety study J Am Med Assoc 284 2000 1247 1255
28. L.A. Smith, A.D. Oldman, H.J. McQuay, and R.A. Moore Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain Pain 86 2000 119 132
29. J.A. Sterne, D. Gavaghan, and M. Egger Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature J Clin Epidemiol 53 2000 1119 1129
30. J-L. Tang, and J.L.Y. Liu Misleading funnel plot for detection of bias in meta-analysis J Clin Epidemiol 53 2000 477 484
31. M.R. Tramèr, R.A. Moore, D.J. Reynolds, and H.J. McQuay Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Pain 85 2000 169 182